PURPOSE: 16α-[(18)F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit. PROCEDURES: Women with newly diagnosed metastatic breast cancer (MBC) from an ER-positive primary tumor were imaged before starting endocrine therapy. FES uptake was evaluated qualitatively and quantitatively, and associated with response and with ER expression. RESULTS: Nineteen patients underwent FES imaging. Fifteen had a biopsy of a metastasis and 15 were evaluable for response. Five patients had quantitatively low FES uptake, six had at least one site of qualitatively FES-negative disease. All patients with an ER-negative biopsy had both low uptake and at least one site of FES-negative disease. Of response-evaluable patients, 2/2 with low FES standard uptake value tumors had progressive disease within 6 months, as did 2/3 with qualitatively FES-negative tumors. CONCLUSIONS: Low/absent FES uptake correlates with lack of ER expression. FES-positron emission tomography can help identify patients with endocrine resistant disease and safely measures ER in MBC.
PURPOSE: 16α-[(18)F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit. PROCEDURES: Women with newly diagnosed metastatic breast cancer (MBC) from an ER-positive primary tumor were imaged before starting endocrine therapy. FES uptake was evaluated qualitatively and quantitatively, and associated with response and with ER expression. RESULTS: Nineteen patients underwent FES imaging. Fifteen had a biopsy of a metastasis and 15 were evaluable for response. Five patients had quantitatively low FES uptake, six had at least one site of qualitatively FES-negative disease. All patients with an ER-negative biopsy had both low uptake and at least one site of FES-negative disease. Of response-evaluable patients, 2/2 with low FES standard uptake value tumors had progressive disease within 6 months, as did 2/3 with qualitatively FES-negative tumors. CONCLUSIONS: Low/absent FES uptake correlates with lack of ER expression. FES-positron emission tomography can help identify patients with endocrine resistant disease and safely measures ER in MBC.
Authors: Robert W Carlson; D Craig Allred; Benjamin O Anderson; Harold J Burstein; Stephen B Edge; William B Farrar; Andres Forero; Sharon Hermes Giordano; Lori J Goldstein; William J Gradishar; Daniel F Hayes; Clifford A Hudis; Steven Jay Isakoff; Britt-Marie E Ljung; David A Mankoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Lori J Pierce; Elizabeth C Reed; Mary Lou Smith; Hatem Soliman; George Somlo; Richard L Theriault; John H Ward; Antonio C Wolff; Richard Zellars; Rashmi Kumar; Dorothy A Shead Journal: J Natl Compr Canc Netw Date: 2012-07-01 Impact factor: 11.908
Authors: P L Porter; A Y El-Bastawissi; M T Mandelson; M G Lin; N Khalid; E A Watney; L Cousens; D White; S Taplin; E White Journal: J Natl Cancer Inst Date: 1999-12-01 Impact factor: 13.506
Authors: J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: A Gennari; S Donati; B Salvadori; A Giorgetti; P A Salvadori; O Sorace; G Puccini; P Pisani; M Poli; D Dani; E Landucci; G Mariani; P F Conte Journal: Clin Breast Cancer Date: 2000-07 Impact factor: 3.225
Authors: Hadi Yaziji; Lynn C Goldstein; Todd S Barry; Robert Werling; Harry Hwang; Georgiana K Ellis; Julie R Gralow; Robert B Livingston; Allen M Gown Journal: JAMA Date: 2004-04-28 Impact factor: 56.272
Authors: Stephanie E Stafford; Julie R Gralow; Erin K Schubert; Kristine J Rinn; Lisa K Dunnwald; Robert B Livingston; David A Mankoff Journal: Acad Radiol Date: 2002-08 Impact factor: 3.173
Authors: Frank I Lin; E M Gonzalez; S Kummar; K Do; J Shih; S Adler; K A Kurdziel; A Ton; B Turkbey; P M Jacobs; S Bhattacharyya; A P Chen; J M Collins; J H Doroshow; P L Choyke; M L Lindenberg Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-21 Impact factor: 9.236
Authors: Gary A Ulaner; Komal Jhaveri; Sarat Chandarlapaty; Vaios Hatzoglou; Christopher C Riedl; Jason S Lewis; Audrey Mauguen Journal: J Nucl Med Date: 2020-07-17 Impact factor: 10.057
Authors: Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott Journal: AAPS J Date: 2018-03-08 Impact factor: 4.009
Authors: Yingbing Wang; Karen L Ayres; Debra A Goldman; Maura N Dickler; Aditya Bardia; Ingrid A Mayer; Eric Winer; Jill Fredrickson; Carlos L Arteaga; José Baselga; Henry C Manning; Umar Mahmood; Gary A Ulaner Journal: Clin Cancer Res Date: 2016-12-23 Impact factor: 12.531
Authors: Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel Journal: Mol Pharm Date: 2016-10-10 Impact factor: 4.939
Authors: Brenda F Kurland; Lanell M Peterson; Jean H Lee; Erin K Schubert; Erin R Currin; Jeanne M Link; Kenneth A Krohn; David A Mankoff; Hannah M Linden Journal: Clin Cancer Res Date: 2016-06-24 Impact factor: 12.531